Leadership

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to recapture the heights of old.

Legos will take over from Roger Dansey, who will begin transitioning to retirement.

A Harvard Business School Healthcare Alumni Association Q&A with Spencer Stuart’s Claudius A. Hildebrand.

Effective February 10, 2025, Mamilli will assume global responsibility for the Informatics function for the Roche Group.

During the transition period, Lykos will work with a number of shareholders to secure financing for an additional Phase III trial of midomafetamine capsules for post-traumatic stress disorder.

Why investing in people and training can help drugmakers deal with six pressing challenges in particular in the year ahead.

Berger joins Gilead with over 25 years of global drug development experience and will oversee the company’s virology, oncology, and inflammation portfolio.

For pharma manufacturers, the primary requirement for working with high-profile clients is matching their organizational level of urgency and organization.

Decisions and strategies related to remote work, AI, and DE&I are especially evolving.

Rafaat Rahmani, president and founder of Lifescience Dynamics, grew up in abject poverty, but such hardships—and a later violent brush with racism—would ultimately end up fueling a determined and entrepreneurial path in the life sciences.

Three key components to scaling quickly—while maintaining purpose.

A Q&A with Dr. Ken Dychtwald, Recipient of the McKinsey Award for his Harvard Business Review article, “It’s Time to Retire Retirement.”

Jan van de Winkel, PhD, president and CEO of Genmab, the longtime innovation engine in antibody drug development, discusses its vision for adding a new business identity: commercial driver.

As chief medical officer, Foley is expected to guide the clinical direction of True Digital Surgery and the advancement of its Digital Surgical Exoscope Platform.

Insights from Takeda, Jazz, Nestlé Health Sciences, Humana, and other healthcare executives

If you wish for your team to be diligent, innovative, and collaborative, you must first exhibit these traits yourself

Findings from hundreds of interviews of exceptional pharma leaders around the world.

How pharma and biotech leaders can navigate today’s challenging landscape—focusing on revamped approaches in business operations, talent strategy and development, and more to meet the evolving demands.

Leaders must address the root causes of negative public perception.

The industry has struggled to recruit talent for years, and the challenge is only getting more difficult. Pharma companies need to recruit differently.

Why this role provides a critical ‘boot camp’ for future pharma leaders.

Classic views on leadership are sometimes still the most effective.

Continuous learning a vital skill for aspiring and established leaders alike.

McCullar discusses his new role as CEO of RegCell.

C-Suites and their boards should remember that digital transformation is a key part of the larger focus of a profound business transformation.

The Alliance for mRNA Medicines is the first and only scientific and policy organization singularly focused on advancing and advocating for global mRNA innovation.

Julie Louise Gerberding, president and CEO of the Foundation for the National Institutes of Health (FNIH) and former lead of the CDC, shares insight into her experience at the CDC and FNIH in this Q&A with Pharm Exec.

In this latest Harvard Business School Healthcare Alumni Association Q&A, JT Saunders, Chief Diversity Officer at global consulting firm Korn Ferry, discusses diversity in pharma, as well as what mentors and mentees should be considering in the workplace.

The core building blocks of trust must be operationalized for pharma companies to strengthen their social contract, deliver business value, and improve patients’ quality of life.

The impact on clinical trial staffing would be particularly significant.